Every Cure

Every Cure Receives Five-Year, $60 Million Commitment Through TED's Audacious Project to Repurpose Medications for Global Impact. Full Press Release: https://lnkd.in/eCcwt4Vn TED Conferences The Audacious Project

Just after I discovered a drug to save my own life, I faced yet another devastating diagnosis—my uncle was diagnosed with metastatic angiosarcoma. When I joined him at his doctor’s appointment, we were told that he likely wouldn’t have much longer to live. Refusing to accept this fate, I dug deep into the research and found a 2013 study that suggested a glimmer of hope. In this small study, four out of five patients with angiosarcoma had increased expression of a protein called PD-L1. This hinted that a drug called a PD-1 inhibitor, typically used for other cancers, might work for him. Eight years ago, my uncle became the first patient that we were aware of to be treated with a PD-1 inhibitor for angiosarcoma. Just last weekend, he walked my cousin down the aisle at her wedding. #cancer #drugrepurposing #raredisease #drugdevelopment

Injecting lidocaine directly into breast cancer tumors resulted in a remarkable 29% reduction in mortality, according to a large randomized control trial involving nearly 1,600 patients! Researchers estimate that this simple, accessible approach could save over 100,000 lives worldwide if widely adopted. As we observe Breast Cancer Awareness Month this October, it’s important to spotlight promising discoveries like this. What's even more exciting is that because similar receptors are present in other cancers, lidocaine could potentially be effective for more than just breast cancer. This is exactly why Every Cure exists—to match affordable, old drugs like lidocaine with devastating diseases like cancer, ensuring that every patient can benefit from lifesaving treatments. #BreastCancerAwarenessMonth #CancerResearch #DrugRepurposing #LifesavingTreatments #EveryCure #HealthcareInnovation #PatientCare

A drug that was studied in the 1990s for Alzheimer's disease but was ultimately abandoned has been repurposed and approved for schizophrenia! The underlying drug was combined with a second existing medication to mitigate some of the initial side effects, making it the first new antipsychotic to reach the market in decades. We were thrilled to hear about Bristol-Myers Squibb's success in giving this old drug new life. These “resurrections” where a drug that failed in one area finds renewed purpose in another– highlight the vast, untapped potential within the pharmaceutical world. At Every Cure, we are committed to uncovering more of these opportunities. We believe countless treatments remain to be rediscovered and repurposed to save lives. #raredisease #drugdevelopment #schizophrenia #Alzheimers

Congratulations to David Fajgenbaum, MD, MBA, MSc (WG'15), and Michael Rovinsky, WG'86, on receiving 2024 WHCMAA Alumni Awards. David is the recipient of the Alumni Achievement Award, and Michael received the Outstanding Service Award. David and Michael will accept their awards at our alumni dinner on Thursday, November 14, which is being held in conjunction with our annual alumni conference. Register for the dinner and conference here: https://lnkd.in/dpy_gZ9T. Note: A quick reminder that the dinner is open to all alumni, not just conference attendees. David is one of the youngest tenured professors in the history of Penn Medicine (University of Pennsylvania Perelman School of Medicine), one of the youngest awardees of multiple top NIH and FDA grants, a national bestselling author of 'Chasing My Cure: A Doctor's Race to Turn Hope Into Action', and he is in his longest remission ever thanks to a precision treatment he identified for idiopathic multicentric #Castlemandisease (iMCD). He's now chasing "every cure" as co-founder of the nonprofit, Every Cure, having identified and/or advanced 15 other treatment approaches for iMCD and cancer. Michael is a healthcare strategist, advisor, and business development executive with more than 37 years of experience and currently serves as Vice President of Strategic Planning for Array Advisors. Since graduation, he has been an unflagging supporter of the Wharton School's Health Care Management (WHCM) Program, strengthening alumni connection to the program through frequent visits for reunions, the WHCM conference, and meetings with students, program leadership, and alumni. He has significantly impacted students in the Program and the Program's visibility through his many years of service as a member of the WHCMAA Board and his ongoing involvement with the Career Development Committee. Congratulations to both alumni!

It was great to sit down with Tina Tan of FirstWord HealthTech in Berlin to discuss Every Cure's mission of unlocking the full potential of existing drugs! Click the link below to read the full article: https://lnkd.in/e9fMnhR2

In the past, we would spend years in the lab working on a single proteomic or genomic sequencing study to uncover one key insight. Now, with the power of artificial intelligence, we can apply AI to the world’s biomedical knowledge—all the research, studies, and discoveries ever made.  By training AI on known drug-disease connections, we can unleash it to find patterns across this vast knowledge graph. Incredibly, what used to take years to analyze one drug for one disease can now be predicted across millions of possibilities in just a few days. At Every Cure, we're harnessing this transformative technology to unlock treatments that are sitting right on the pharmacy shelves, ensuring that existing drugs reach the patients who need them most. Our mission is to accelerate the discovery of these life-saving connections and deliver hope to millions of patients waiting for cures. #drugdevelopment #raredisease #drugdiscovery #pharma

At Every Cure we’re excited about the launch of the Rare Disease Innovation Hub at the FDA and its potential to accelerate cures for the millions of patients suffering from diseases with no approved treatment. You can see my thoughts here:

At Every Cure, we're uncovering what we call "unsung heroes"—drugs that have already demonstrated their effectiveness in helping patients, yet remain underutilized. Leveraging our cutting-edge AI platform, we identify these promising drug repurposing opportunities where the science is compelling and clinical trials confirm their efficacy. These are the medications that have been overlooked, but are ready to move to the forefront of treatment options. Our goal is to integrate these treatments into clinical guidelines and raise awareness, ensuring that patients can benefit from them as soon as possible. #raredisease #pharma #drugdevelopment #drugrepurposing

This past week Every Cure CEO Grant W Mitchell, MD, MBA was in Berlin keynoting at Frontiers Health! Thank you to Francis Namouk for grabbing this picture!